A detailed history of Victory Capital Management Inc transactions in Alpine Immune Sciences, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 45,064 shares of ALPN stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,064
Holding current value
$0
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$17.75 - $41.6 $799,886 - $1.87 Million
45,064 New
45,064 $1.79 Million
Q2 2020

Aug 07, 2020

SELL
$2.77 - $12.1 $4,282 - $18,706
-1,546 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$2.15 - $4.41 $75 - $154
-35 Reduced 2.21%
1,546 $4,000
Q4 2019

Feb 04, 2020

SELL
$2.45 - $3.87 $321,003 - $507,055
-131,022 Reduced 98.81%
1,581 $5,000
Q3 2019

Nov 12, 2019

BUY
$3.5 - $5.0 $5,533 - $7,905
1,581 Added 1.21%
132,603 $520,000
Q2 2019

Aug 15, 2019

SELL
$4.08 - $7.75 $14,361 - $27,280
-3,520 Reduced 2.62%
131,022 $552,000
Q1 2019

May 03, 2019

SELL
$4.09 - $7.19 $6,257 - $11,000
-1,530 Reduced 1.12%
134,542 $923,000
Q4 2018

Feb 05, 2019

BUY
$3.68 - $6.07 $261,206 - $430,848
70,980 Added 109.05%
136,072 $501,000
Q3 2018

Nov 01, 2018

SELL
$5.68 - $8.59 $19,482 - $29,463
-3,430 Reduced 5.01%
65,092 $412,000
Q2 2018

Aug 02, 2018

SELL
$7.16 - $10.05 $27,064 - $37,989
-3,780 Reduced 5.23%
68,522 $519,000
Q1 2018

May 04, 2018

BUY
$7.95 - $11.65 $164,970 - $241,749
20,751 Added 40.25%
72,302 $578,000
Q4 2017

Feb 01, 2018

BUY
$9.65 - $12.65 $113,860 - $149,257
11,799 Added 29.68%
51,551 $577,000
Q3 2017

Oct 27, 2017

BUY
$8.0 - $11.6 $318,016 - $461,123
39,752
39,752 $461,000

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.